File photo: Staff members walk past the waiting area of the assisted reproductive centre at the Beijing Perfect Family Hospital, which specialises in fertility treatments, in Beijing, China, 6 April 2023; Credit: Reuters/Tingshu Wang/File Photo

HONG KONG (Reuters) - On Thursday 15 June 2023, Beijing's government announced that it would cover sixteen types of assisted reproduction technology under the city's health care system from 1 July 2023, the latest move by authorities to boost China's flagging birth rate.

In vitro fertilisation (IVF), embryo transplantation, freezing and storing semen are some of the treatments that would be included under basic insurance, said Du Xin, deputy director of Beijing's Municipal Medical Insurance Bureau.

The measure comes as China grapples to stem a decline in births after posting its first population drop in six decades. The number of newborns dropped to a record low of 6.77 per 1,000 people last year and is expected to decline further in 2023.

China's National Health Commission last August issued guidance to provinces on reforming policies to support fertility rates.

Liaoning, a province in China's northeast, said in May 2023 that it would include assisted reproduction technologies from 1 July.

Beijing's announcement also comes ahead of a court verdict for Teresa Xu, an unmarried 35-year old Chinese woman who sued a Beijing public hospital for violating her rights by refusing to freeze her eggs because she is unmarried.

Concerned about China's rapid ageing, government political advisers proposed in March 2023 that single and unmarried women should have access to egg freezing and IVF treatment, among other services.

It is difficult for unmarried women across the country to access fertility treatments such as IVF and egg freezing technologies due to a national rule that they must be married.

Some private clinics in provinces such as in the southwestern Sichuan province have already begun permitting IVF due to falling births.

Liberalising fertility treatments nationwide could unleash more demand in what is already the world's biggest market, and strain limited fertility services, said investors and industry executives.